The scientists used two preclinical models of absence epilepsy to test their hypothesis. Both models feature animals genetically predisposed to absence seizures that consistently and reliably develop ...

This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

The story of Eric, a nine year old boy with several short episodes of blank stare in a day displays an example of Childhood Absence Epilepsy. His mother apparently had similar episodes in childhood.

Absence seizure, formerly known as petit mal seizure, is a type of short seizure that usually causes a person to briefly lose focus, stare into space, and lose awareness of their surroundings. These ...

Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (DRUG), a biotechnology company focused on developing novel therapies for neurological and ...